If you weren’t confused enough yet, consider that 18 states have laws allowing for medical CBD use (also known as “non-psychoactive medical cannabis”) for a select number of conditions, such as treatment-resistant epilepsy in children. Similar to the areas where medical marijuana is legal, you have to obtain a prescription to get CBD in these states, with the additional caveat that the product cannot contain high levels of THC.
Our products are not approved by the Food and Drug Administration (FDA) and may not be used to diagnose, treat, or prevent any disease. Due to the limited amount of clinical evidence regarding hemp-derived extracts in treating disease states, we cannot offer any type of comment or recommendation. We do, however, recommend you research the National Academies of Science (NAS) publish report regarding the current state of evidence regarding cannabis research: http://nationalacademies.org/hmd/Reports/2017/health-effects-of-cannabis-and-cannabinoids.aspx
The passing of SB 218 through the Kentucky legislature created a new subsection of KRS 260.850m to 260.289, in which the Industrial Hemp Advisory Board outlines the purpose of an industrial hemp research program, establish license provisions, and create new requirements and license application procedures. This state’s approach is for the potential medical and industrial applications.
More human studies are needed to fully understand the range of risks and side effects that CBD oil may cause. Studies of CBD oil aren’t common. This is partially because Schedule 1 substances like cannabis are highly regulated, causing some obstacles for researchers. With the legalization of marijuana products, more research is possible, and more answers will come.